Reply to “Design–analysis mismatch in the analysis of longitudinal HER2 data in breast cancer”

March 30, 2026Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to clarify the appropriateness of statistical methods used in assessing HER2 status for predicting treatment outcomes in breast cancer.
Analyzed baseline HER2 status from single pretreatment core biopsies.
Used logistic regression and Cox models for outcome predictions.
Included patients who completed planned neoadjuvant chemotherapy without distant metastasis or death.
HER2 status was identified as a predictor of pathologic complete response and survival.
The design eliminated concerns about immortal time bias.
Compliance with reporting standards (STROBE guidelines) was maintained throughout the analysis.

This analysis explores HER2 status's role in predicting treatment responses in breast cancer, suggesting methodological precision is vital.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Fangmeng Fu (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share